These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 6728123)

  • 1. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol.
    Morgan DG; Sinha YN; Finch CE
    Neuroendocrinology; 1984 May; 38(5):407-10. PubMed ID: 6728123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone.
    Lazareno S; Nahorski SR
    Eur J Pharmacol; 1982 Jul; 81(2):273-85. PubMed ID: 7117377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in in vivo (3H) spiperone binding in the rat hippocampal formation and striatum after repeated treatment with haloperidol.
    Bischoff S
    Experientia; 1981; 37(9):1008-9. PubMed ID: 7297644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
    Severson JA; Robinson HE; Simpson GM
    Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H; Wedel I
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovine prolactin administration modifies [3H]spiperone binding to striatal membranes of rabbits.
    Eva C; Blengio M; Ferretti C; Muccioli G; Portaleone P
    Brain Res; 1982 Nov; 251(2):388-90. PubMed ID: 7139336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat.
    Simpson MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1986 Oct; 35(20):3501-6. PubMed ID: 3768037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Paulose CS; Mishra RK
    Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic sulpiride on striatal spiperone binding.
    Bannet J; Gillis S; Ebstein RP; Belmaker RH
    Int Pharmacopsychiatry; 1980; 15(6):334-7. PubMed ID: 7298264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
    Rupniak N; Hong M; Mansfield S; Fleminger S; Dyer R; Jenner P; Marsden CD
    Eur J Pharmacol; 1983 Sep; 93(3-4):195-200. PubMed ID: 6139285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the binding of [3H]spiperone and [3H]domperidone in homogenates of mammalian retina and caudate nucleus.
    Watling KJ; Iversen LL
    J Neurochem; 1981 Nov; 37(5):1130-43. PubMed ID: 7299392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists.
    Hruska RE
    Brain Res Bull; 1986 Mar; 16(3):331-9. PubMed ID: 3708389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
    Globus M; Bannet J; Lerer B; Belmaker RH
    Psychopharmacology (Berl); 1982; 78(1):81-4. PubMed ID: 6815701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.
    Meller E; Bohmaker K; Goldstein M; Schweitzer JW; Friedhoff AJ
    Eur J Pharmacol; 1985 Mar; 109(3):389-94. PubMed ID: 3157587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of chronic haloperidol to affect prolactin secretion due to acute haloperidol administration.
    Parati EA; Parenti M; Locatelli V; Penalva A; Tamminga C; Müller EE
    Pharmacol Res Commun; 1985 May; 17(5):407-15. PubMed ID: 4034625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic influences on pituitary responsiveness to haloperidol in mice.
    Morgan DG; Randall JS; Telford NA; Gordon MN; Sinha YN; Finch CE; Randall PK
    Psychoneuroendocrinology; 1987; 12(3):211-8. PubMed ID: 3615750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
    Zahniser NR; Dubocovich ML
    J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.